Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $54
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Oppenheimer analyst Jeff Jones maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $57 to $54.
Oppenheimer analyst Jeff Jones maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $57 to $54.